SEC 13F Intelligence

Atlas Venture Life Science Advisors, LLC / DYN

Atlas Venture Life Science Advisors, LLC’s Dyne Therapeutics Inc Position

Does Atlas Venture Life Science Advisors, LLC own Dyne Therapeutics Inc (DYN)? Yes — 9.13M shares worth $166M (+20.95% of its 13F portfolio) as of Q1 2026.

Position Value
$166M
Q1 2026
Shares
9.13M
% of Portfolio
+20.95%
Quarters Held
17
currently held

Position History DYN

Reported value by quarter
Q1 ’22: $86MQ1 ’22Q2 ’22: $61MQ3 ’22: $113MQ4 ’22: $114MQ4 ’22Q1 ’23: $114MQ2 ’23: $111MQ3 ’23: $89MQ3 ’23Q4 ’23: $131MQ1 ’24: $228MQ2 ’24: $283MQ2 ’24Q3 ’24: $288MQ4 ’24: $189MQ1 ’25: $96MQ1 ’25Q2 ’25: $87MQ3 ’25: $116MQ4 ’25: $179MQ4 ’25Q1 ’26: $166Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20269.13M$166M+20.95%
Q4 20259.13M$179M+20.64%
Q3 20259.13M$116M+15.35%
Q2 20259.13M$87M+13.12%
Q1 20259.13M$96M+18.30%
Q4 20248.02M$189M+23.05%
Q3 20248.02M$288M+26.71%
Q2 20248.02M$283M+29.80%
Q1 20248.02M$228M+21.01%
Q4 20239.89M$131M+15.66%
Q3 20239.89M$89M+13.72%
Q2 20239.89M$111M+13.84%
Q1 20239.89M$114M+15.42%
Q4 20229.87M$114M+13.78%
Q3 20228.93M$113M+12.52%
Q2 20228.93M$61M+10.26%
Q1 20228.93M$86M+10.89%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Atlas Venture Life Science Advisors, LLC’s full portfolio or all institutional holders of DYN.